Europe’s Divisional Patent Trap: How Big Pharma Delays Generics Without Ever Losing in Court
When a European patent dies — formally, irrevocably, at the hands of the European Patent Office’s Technical Board of Appeal […]
Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching
When Johnson & Johnson’s multiple myeloma franchise Darzalex (daratumumab) generated roughly $10 billion in global revenue in 2024, it stood
Pharm to Table: Map Supply Chains and Predict Drug Shortages Using Patent Data
We rarely know where our medicines originate. The global pharmaceutical supply chain is an opaque network of chemical synthesis facilities,
Pharm to Table: Map Supply Chains and Predict Drug Shortages Using Patent Data Read Post »
Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors
1. Why Patent Expiry Forecasting Is a Revenue-Critical Discipline ‘Between 2025 and 2030, approximately 190 drugs will lose market exclusivity,
Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors
1. The $2.8 Trillion Arithmetic: Market Structure and Strategic Stakes The global pharmaceutical market reached approximately $1.6 trillion in 2024
The Generic Drug Approval Process: A Complete Technical and Strategic Reference for Pharma IP, R&D, and Investment Teams
A deep dive covering the ANDA pathway, EU MAA procedures, bioequivalence science, Paragraph IV litigation strategy, patent cliff analysis, evergreening
Find Qualified API Suppliers for Off-Patent Drugs: The Patent & Regulatory Intelligence Playbook
The $236 Billion Race Most Procurement Teams Are Losing Between 2025 and 2030, more than $236 billion in branded pharmaceutical
CDMO Project Management: The Definitive Playbook for Pharma IP Teams, R&D Leads, and Institutional Investors
I. Market Context: Why the CDMO Sector Is Repricing The global pharmaceutical CDMO market hit approximately $181.93 billion in 2025,
Your Drug’s Patent Expired. Now What? The Complete Strategic Guide to Patent Cliffs, Lifecycle Defense, and Post-Exclusivity Competition
1. The Cliff Everyone Sees Coming — and Still Falls Off Every branded pharmaceutical product carries a date of death.
